The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis
Abstract
The present study was planned to evaluate the chemotherapeutic potential of nebulized solid lipid particles (SLPs) incorporating rifampicin, isoniazid and pyrazinamide against experimental tuberculosis. The SLPs prepared by the "emulsion solvent diffusion" technique possessed a favourable mass median aerodynamic diameter suitable for bronchoalveolar drug delivery. Following a single nebulization to guinea pigs, therapeutic drug concentrations were maintained in the plasma for 5 days and in the organs (lungs, liver and spleen) for 7 days whereas free drugs were cleared by 1-2 days. The mean residence time and drug bioavailability were improved several-fold in the case of drug-loaded SLPs. A similar pharmacokinetic profile was observed in Mycobacterium tuberculosis-infected guinea pigs. On nebulization of drug-loaded SLPs to infected guinea pigs at every 7th day, no tubercle bacilli could be detected in the lungs/spleen after 7 doses of treatment whereas 46 daily doses of orally administered drugs were required to obtain an equivalent therapeutic benefit. Further, there was no evidence of any biochemical hepatotoxicity. Thus, nebulization of SLP-based antitubercular drugs forms a sound basis for improving drug bioavailability and reducing the dosing frequency for better management of pulmonary tuberculosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a similar approach, Pandey and Kuller demonstrated that SLNs made up of stearic acid may also be used as potential delivery vehicles for INH, RIF, and PZA.”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [217]
In the citing paper
“The pulmonary delivery of drugs encapsulated in SLNs through nebulization resulted in specific deposition in the lungs and the detection of the drug in other organs for up to 7 days.217”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [217]
In the citing paper
“Interestingly, all these formulations showed sustained release for up to 72 h with an initial burst drug release pattern of less than 20% in the first 6 h.”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [217]
In the citing paper
“Researchers have developed nebulized solid lipid particles 129 and sodium alginate nanoparticles 130 incorporating rifampicin, isoniazid and pyrazinamide to improve targeted bioavailability in the lungs and reduce hepatotoxicity.”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [129]
Citations
Cites
1 retracted
Dhuley, J. N. (1999) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.1999.tb01347.x · Cited by 4
RetractedSahoo, S. K., Panyam, J., Prabha, S., & Labhasetwar, V. D. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00127-x · Cited by 1,008
Schwarz, C., Mehnert, W., Lucks, J. S., & Müller, R. H. (1994) · Journal of Controlled Release · doi:10.1016/0168-3659(94)90047-7 · Cited by 574
Pandey, R. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg477 · Cited by 389
Self-citationHu, F., Yuan, H., Zhang, H. H., & Fang, M. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00081-9 · Cited by 284
Pandey, R., Zahoor, A., Sharma, S., & Khuller, G. K. (2003) · Tuberculosis · doi:10.1016/j.tube.2003.07.001 · Cited by 220
Self-citationLymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles
Videira, M. A., Botelho, M. F., Santos, A. C., Gouveia, L. F., Pedroso de Lima, J. J., & Almeida, A. J. (2002) · Journal of Drug Targeting · doi:10.1080/1061186021000054933 · Cited by 213
Sharma, R., Saxena, D., Dwivedi, A. K., & Misra, A. (2001) · Pharmaceutical Research · doi:10.1023/a:1012296604685 · Cited by 201
Solid lipid nanoparticles (SLN) for controlled drug delivery
Müller, R. H., Freitas, C., Mühlen, A. Z., & Mehnert, W. (1996) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(97)86243-4 · Cited by 174
Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization
Jenning, V., Lippacher, A., & Gohla, S. (2002) · Journal of Microencapsulation · doi:10.1080/713817583 · Cited by 163
Research works printed but not linked: 1
- Scott, 1967, Fluorimetric determination of isonicotinic acid hydrazide in plasma, J Lab Clin Med, 70, 355
Cited by
Sorted by citations
Huh, A. J., & Kwon, Y. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.002 · Cited by 1,920
Drug delivery systems: An updated review
Tiwari, G., Tiwari, R., Bannerjee, S., Bhati, L., Pandey, S., Pandey, P., & Sriwastawa, B. (2012) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.96920 · Cited by 1,671
Barua, S., & Mitragotri, S. (2014) · Nano Today · doi:10.1016/j.nantod.2014.04.008 · Cited by 1,288
Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Puri, A., Loomis, K. H., Smith, B. J., Lee, J. H., Yavlovich, A., Heldman, E., & Blumenthal, R. P. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,099
Development of Nanoparticles for Antimicrobial Drug Delivery
Zhang, L., Pornpattananangkul, D., Hu, C.-M., & Huang, C.-W. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710790416290 · Cited by 904
Metadata
- Authors
- Pandey, R., & Khuller, G. K.
- Affiliations
- Post Graduate Institute of Medical Education and Research (IN)
- Corresponding author
- Khuller, G.K.
- ORCID
- Pandey, Rajesh
- Venue
- Tuberculosis
- Publisher
- Elsevier BV
- Published
- 2005-07
- Volume
- 85
- Issue
- 4
- Pages
- 227-234
- ISSN
- 1472-9792 (ISSN-L)
- OpenAlex
- W2137397041
- Cited by
- 318
- References
- 24
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 9 · 2023: 13 · 2022: 17 · 2021: 21 · 2020: 18 · 2019: 19 · 2018: 24 · 2017: 18 · 2016: 24 · 2015: 13 · 2014: 26 · 2013: 20 · 2012: 14
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Tuberculosis (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Department of Science and Technology, Ministry of Science and Technology, India
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- solid lipid particles, pulmonary tuberculosis, nebulized drug delivery, rifampicin, isoniazid, pyrazinamide, antitubercular agents, emulsion solvent diffusion, aerosol drug delivery, pharmacokinetics, drug bioavailability, Mycobacterium tuberculosis, guinea pig model, hepatotoxicity
- MeSH terms
- Administration, Inhalation, Animals, Antitubercular Agents, Biological Availability, Drug Carriers, Guinea Pigs, Isoniazid, Lipids, Pyrazinamide, Rifampin, Tuberculosis, Drug Delivery Systems, Area Under Curve, Nanostructures
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
